While early, the findings suggest the therapy could be superior to Novartis’ Vijoice at treating “vascular anomalies,” a cluster of chronic conditions with few available treatments.

While early, the findings suggest the therapy could be superior to Novartis’ Vijoice at treating “vascular anomalies,” a cluster of chronic conditions with few available…

Relay Therapeutics’ first data readout for zovegalisib in a rare genetic disease beat Wall Street expectations, expanding the PIK3α inhibitor’s R&D prospects beyond breast cancer.

Relay Therapeutics reported early Phase 2 data showing lesion reduction and symptom improvement with zovegalisib.